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Background: The roles of caspase 3 on the kainic acid-mediated neurodegeneration, dendritic plasticity alteration,
neurogenesis, microglial activation and gliosis are not fully understood. Here, we investigate hippocampal changes
using a mouse model that receive a single kainic acid-intracerebral ventricle injection. The effects of caspase 3
inhibition on these changes were detected during a period of 1 to 7 days post kainic acid injection.
Result: Neurodegeneration was assessed by Fluoro-Jade B staining and neuronal nuclei protein (NeuN) immunostaining.
Neurogenesis, gliosis, neuritic plasticity alteration and caspase 3 activation were examined using immunohistochemistry.
Dendritic plasticity, cleavvage-dependent activation of calcineurin A and glial fibrillary acidic protein cleavage were
analyzed by immunoblotting. We found that kainic acid not only induced neurodegeneration but also arouse
several caspase 3-mediated molecular and cellular changes including dendritic plasticity, neurogenesis, and gliosis.
The acute caspase 3 activation occurred in pyramidal neurons as well as in hilar interneurons. The delayed caspase
3 activation occurred in astrocytes. The co-injection of caspase 3 inhibitor did not rescue kainic acid-mediated
neurodegeneration but seriously and reversibly disturb the structural integrity of axon and dendrite. The kainic
acid-induced events include microglia activation, the proliferation of radial glial cells, neurogenesis, and calcineurin
A cleavage were significantly inhibited by the co-injection of caspase 3 inhibitor, suggesting the direct involvement of
caspase 3 in these events. Alternatively, the kainic acid-mediated astrogliosis is not caspase 3-dependent, although
caspase 3 cleavage of glial fibrillary acidic protein occurred.
Conclusions: Our results provide the first direct evidence of a causal role of caspase 3 activation in the cellular
changes during kainic acid-mediated excitotoxicity. These findings may highlight novel pharmacological strategies
to arrest disease progression and control seizures that are refractory to classical anticonvulsant treatment.
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Epileptogenesis is the process of epilepsy development
which is characterized by recurrent seizures following an
initial insult, such as status epilepticus (SE). This process
requires intricate molecular, cellular and hippocampal
network reorganization before the first spontaneous seiz-
ure occurs. The changes among epileptogenesis include
neurodegeneration, neurogenesis, axonal sprouting, den-
dritic plasticity alteration, and gliosis [1-6].
Kindling is a commonly used model for the develop-
ment of seizures and epilepsy. kainic acid (KA) is one of
the most common chemoconvulsants used to create SE
models of temporal lobe epilepsy (TLE). Hippocampal
lesions in this model are similar to the hippocampal
sclerosis observed in humans with TLE [7-10]. KA is
commonly administered systemically to cause sustained
neuronal depolarization and seizure generation with a
high mortality rate [11]. To reduce mortality, KA may
be alternatively injected into lateral ventricle [12].
Hippocampus is an important structure in the patho-
physiology of epilepsy. Principal neurons and interneurons
are two major groups of neurons in the hippocampal cor-
tex. Most of the principal neurons, such as pyramidal neu-
rons, form excitatory synapse on the remote neurons,
whereas the interneurons form inhibitory synapses on
principal neurons and other interneurons to prevent the
generation of convulsions. Histologically, hippocampal
cortex can be divided into CA1-CA4 fields, which con-
tains small pyramidal neurons. The circulation of nerve
impulses is formed between CA1-CA4 and enthorinal cor-
tex [13]. The initial limbic seizures increase hippocampal
neurogenesis from radial glial cells [14,15]. Prolonged sei-
zures, however, result in aberrant migration and connec-
tion of newly born neurons [16,17] and lead to recurrent
excitatory circuitry [18]. Conversely, chronic recurrent
spontaneous seizures are associated with substantially re-
duced neurogenesis that coexists with learning and mem-
ory impairments [19].
The involvement of astrogliosis in epileptogenesis may
be attributable to altered dynamic signaling between neu-
rons, astrocytes and several astrocytic membrane proteins
[20]. SE may stimulate reactive astrocytes to proliferate
and express more glial fibrillary acidic protein (GFAP)
[21], which is associated with altered glutamate uptake
and calcium signaling [22]. Morphologically, SE causes
thickening and overlapping of astroglial processes and loss
of astroglial domains [23]. Nevertheless, the molecular
link between initial insults and later changes including
neurodegeneration, neurogenesis, synaptic plasticity alter-
ation, and astrogliosis, remains to be elucidated.
Caspase 3 is implicated in the regulation of synaptic
plasticity alteration [24], cytoskeletal remodeling [25],
and the differentiation of glial cells [26] and stem cells
[27]. Notably, localized caspase 3 activity that causessynaptic failure has been observed in vitro [28], but the
molecular mechanism linking caspase 3 activity to syn-
aptic loss in epileptogenesis is unclear. Furthermore, al-
though caspase 3-mediated cleavage of astrocytic GFAP
has been previously detected in reactive or degenerating
astrocytes [27,29], the effects of caspase 3 on reactive as-
trocytes or radial glial cells during epileptogenesis re-
quire further investigation. To verify the role of caspase
3 in neurodegeneration, neurogenesis, synaptic plasticity,
and astrogliosis during the early phase of epileptogen-
esis, the specific inhibitor of caspase 3 was applied onto
an SE-induced epilepsy model which kainic acid (KA) is
administered via intracerebral ventricle (icv) injection.
Our data suggests that caspase 3 activity is crucial for
cellular alterations during epileptogenesis.
Methods
Animals and treatment
The Institutional Animal Care and Use Committee at
the National Research Institution of Chinese Medicine
approved the animal protocol (IACUC No: P-99-18).
The outbred CD-1 (ICR) mice are selected for this study
due to that they are vulnerable to neurodegeneration
[30]. Six week-old male CD-1 mice were housed for 1
week under standard conditions at 25 ± 2°C with a 12-h
light/dark cycle and were allowed free access to water
and standard chow. Administration (icv) of KA (Merck)
was performed unilaterally on male CD-1 mice (6 weeks
old). The mice were anesthetized with intraperitoneal
(ip) chloral hydrate (Sigma; 0.4 g/kg body weight, main-
tained with 0.1 g/kg hourly) and fixed into a stereotaxic
apparatus. The dorsal surface of the skull was exposed
with a midline incision, and a burr hole was drilled at
the following coordinates: anteroposterior, 0.22 mm cau-
dal to bregma and 1 mm right lateral to midline. A 10-μl
Hamilton syringe fitted with a 25-gauge needle and filled
with KA alone or combined with caspase 3 inhibitor
(DEVD-CHO, Insolution Caspase-3 inhibitor I, cell per-
meable, 1 mg/100 μl, Merck) solution in saline was
placed over the burr hole and lowered 2.5 mm into the
surface of the brain, and the solution was injected at a
rate of 0.2 μl/min. The needle was then left in place for
2 min before it was slowly retracted. Control animals
were injected with saline. The first seizure lasting for at
least half hour was used to identify the occurrence of
SE. The proper KA amount for KA-icv-injection ex-
periment was determined by the profile of KA-induced
seizure after the mice to regain consciousness from
anesthetization. The seizure profile was determined ac-
cording to Racine’s scale [31]: stage 0, no response or be-
havior arrest; stage 1, chewing or facial twitches; stage 2,
chewing and head nodding or wet dog shakes; stage 3,
unilateral forelimb clonus; stage 4, bilateral forelimb
clonus and rearing; stage 5, bilateral forelimb clonus,
Figure 1 (See legend on next page.)
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Figure 1 The neurodegeneration in the hippocampus of the KA-icv-injected mice. CD-1 mice received KA-icv-injections and were sacrificed
at day 1, 3, 5, and 7 post KA-injection (KA-d1, KA-d3, KA-d5, and KA-d7). For control, the mice were sacrificed at day 7 post vehicle-injection (veh).
The neurodegeneration in the ipsilateral side of CA1, CA3, and DG was examined by FJB-staining (FJB, green) and immunostaining with anti-NeuN
(NeuN, red) antibody. Cell nuclei were stained with Hoechst 33258 (blue). Panel (a) shows the representative fluorescent images of the ipsilateral side
of CA1, CA3 and DG. The location of pyramidal layer (Py), striatum radiatum (SR). Molecular layer (Mo), and Hilus (Hi) are indicated in the images of the
left lane of the panels. The number of FJB-positive (b) and NeuN-positive (c) neurons in the ipsilateral side of CA1 (white columns), CA3 (grey columns),
and DG (black columns) were calculated using MetaMorph software. The results are the mean ± S.D. from 8 images. The data in panel (b) are
the percentages relative to the day 1 post injection. The data in panel (c) are the percentages relative to the vehicle injection. Significant differences
between day 1 post injection and day 3, 5 and 7 post injection in panel (b) are indicated by #, P < 0.001. Significant differences between vehicle
injection and KA injection in panel (c) are indicated by *, P < 0.001.
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termined as 2 μl (0.4 μg). The proper caspase 3 inhibitor
amount was set as 1 μl (10 μg) base on the previous
study [32,33].
Tissue processing
At day 1, 3, 5, and 7 post KA-injection and day 7 post
vehicle-injection as control, mice were deeply anesthe-
tized with chloral hydrate and perfused through the
heart with 30 ml of saline followed by 30 ml of fixative
solution containing 4% formaldehyde in saline. The
brain was removed, post-fixed in 4% formaldehyde for
18 h at 4°C and cryoprotected in 30% sucrose solution
in 0.1 M phosphate-buffered saline (PBS). A cryostat
was used to cut 30-μm coronal sections through the dor-
sal hippocampus, which were collected serially in PBS.
Fluoro-Jade B staining
Fluoro-Jade B (FJB) has been used for the histological
staining of degenerating neurons [34,35]. For staining
the KA-mediated neurodegeneration, brain sections were
mounted on polylysine-coated glass slides and fully dried.
The sections were rehydrated by immersion in 100% etha-
nol, 70% ethanol, and distilled water for 1 min each. The
slides were then transferred to a solution of 0.06% potas-
sium permanganate for 15 min on a horizontal shaker,
rinsed for 1 min in distilled water, and then incubated in a
solution of 0.0004% FJB (Invitrogen) for 20 min at room
temperature. The sections were rinsed 3 times for 1 min
each in distilled water, and the slides were fully dried. The
slides were cleared by immersion in xylene for at least
1 min before cover slipping. Digital images were acquired
using a confocal laser scanning microscope (Leica CS SP,
Waltlar, Germany and Zeiss LSM780, Jena, Germany)
with excitation at 488 nm and emission at 525 nm.
Immunohistochemistry
Brain sections were incubated in blocking solution (PBS
containing 5% normal donkey serum, 2% Triton X-100,
0.02% bovine serum albumin, BSA) overnight at 4°C and
left overnight at 4°C in staining solution (PBS containing
5% normal goat serum, 0.25% Triton X-100, 0.02% BSA)
with primary antibodies, including mouse monoclonalantibody to GFAP (Invitrogen); rabbit polyclonal anti-
body to doublecortin (Abcam); goat monoclonal anti-
body to ionized calcium-binding adaptor molecule-1
(Iba-1, Abcam); and rabbit polyclonal antibody to active
caspase 3 (R&D Systems). Sections were then incubated
in staining solution containing Hoechst33258 (Invitrogen,
2 μg/ml), Fluorescein isothiocyanate-conjugated donkey
anti-mouse IgG and RRX-conjugated donkey anti-rabbit
IgG or cy5-conjugated donkey anti-goat IgG (1:200;
Jackson ImmunoResearch) in the dark overnight at 4°C.
Sections were then washed in PBS and mounted with
Aqua Poly/Mount (Polyscience Inc., Warrington, PA,
USA).
Quantitative immunofluorescence analysis
All analyses were calculated within a field (250 × 250 μm2)
of Cornu Ammonis (CA)1, CA3 and dentate gyrus (DG)
of 3 series hippocampal slices every brain in a range of
bregma −1.34 to −1.49. The numbers of FJB-positive neu-
rons were manually counted. Because the control sample
did not have any degenerating cells, the number of FJB-
positive cells at day 1 post KA injection was defined as
100% degeneration, and the values from other time points
were calculated as the percentage relative to it. Meta-
Morph Image System and Microsoft Excel were used to
assess the images and quantify the relative florescent in-
tensity. The grayscale values relative to the highest con-
centration of fluorescence and the lack of fluorescent
marker in the section were defined as 100% and 0% dens-
ity values, respectively. The expression of GFAP and Iba-1
was calculated from the immunoreactivity (IR) of each
protein that displayed as the optical density (arbitrary
unit) of each image.
Postsynaptic density (PSD) preparation
The brain was rapidly dissected, and the hippocampus
was homogenized in 10 volumes of H-Buffer (320 mM
sucrose, 2 mM EDTA, 20 mM Tris–HCl [pH 7.4], 1 mM
PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin) with 30
strokes with a tight-fitting glass Dounce tissue grinder
(5 ml, Wheaton). The homogenate was centrifuged at
1,000 × g for 10 min, and the resulting supernatant was
centrifuged at 13,000 × g for 20 min. The pellet was
Figure 2 The caspase 3 activation in the hippocampus of the KA-icv-injected mice. CD-1 mice received KA-icv-injections and were sacrificed
at day 1, 3, 5, and 7 post KA-injection (KA-d1, KA-d3, KA-d5, and KA-d7). For control, the mice were sacrificed at day 7 post vehicle-injection (veh).
The caspase 3 activation and the reactive astrocytes in the ipsilateral side of CA1, CA3, and DG was examined by immunostaining with anti-active
caspase 3 (aCas3, red) and anti-GFAP (green) antibodies. Cell nuclei were stained with Hoechst 33258 (blue). Panel (a) shows the representative
photograph of the partial co-localization of active caspase 3 (aCas3) and GFAP in the ipsilateral side of CA1and DG at day 5 and 7 post KA-injection.
The location of pyramidal layer (Py), striatum radiatum (SR). Molecular layer (Mo), and Hilus (Hi) are indicated in left lane of the panels. Arrows indicate
the representative colocalization of aCas3-IR with astrocytes and radial glial cells in CA1 and DG, respectively. Arrow heads indicate the activation of
capsease 3 in pyramidal neurons in CA1. The IR of non-astroglial (b), astroglial (c) active caspase 3 in the ipsilateral side of CA1 (white columns), CA3
(grey columns), and DG (black columns) were calculated using MetaMorph software. The data are presented as the percentage relative to the vehicle
injection. The results are the mean ± S.D. from 8 images. The data are the percentages relative to the vehicle injection. Significant differences between
vehicle injection and KA injection are indicated by ***, P < 0.001.
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Figure 3 The microglial activation in the hippocampus of KA-icv-injected mice. CD-1 mice received KA-icv-injections and were sacrificed at
day 1, 3, 5, and 7 post KA-injection (KA-d1, KA-d3, KA-d5, KA-d7). For control, the mice were sacrificed at day 7 post vehicle-injection (veh). The
microglial activation in the ipsilateral side of CA1, CA3, and DG was examined by immunostaining with anti-Iba-1 (red) and anti-GFAP (green)
antibodies. Cell nuclei were stained with Hoechst 33258 (blue). The representative images of the ipsilateral side of CA1, CA3 and DG area are
shown (a). The location of pyramidal layer (Py), striatum radiatum (SR). Molecular layer (Mo), and Hilus (Hi) are indicated in the left lane of the
panels. The IR of GFAP (b) and Iba-1 (c) in 250 μm × 250 μm field in CA1 (white columns), CA3 (gray columns) and DG (black columns) were
calculated. The results are the mean ± S.D. from 8 images. Significant differences between the control (veh) and the KA injection are indicated
by *, P < 0.05; **, P < 0.01; ***, P < 0.001. Significant differences between day 1 post KA injection and day 3 post KA injection in panel d are
indicated by #, P < 0.05; ##, P < 0.01.
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Triton-X 100, 2 mM EDTA, 20 mM Tris–HCl [pH 7.4],
1 mM PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin) and
agitated for 1 hr at 4°C. The extracts were centrifuged at
100,000 × g for 1 h. The resulting pellet was resuspended
in 0.1 volume of buffer containing 1% SDS, 2 mM EDTA,
and 20 mM Tris–HCl (pH 7.4). Then, 0.9 volume of TET
buffer was added, and the extracts were agitated for 1 hr
at 4°C, sonicated and incubated on ice for 20 min. The
samples were centrifuged at 11,500 × g for 10 min, and
the protein concentration of the resulting supernatant was
determined.
Immunoblots
For Western blot analysis, samples (6 μg protein) were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (15% gels) and were then transferred to
PVDF membranes. The primary antibodies used were as
follows: mouse monoclonal antibody to GFAP (BD Bio-
science), PSD-95 (Millipore), actin (Invitrogen), rabbit
polyclonal antibody to glutamate receptor 1 (GluR1),
NMDA receptor 1 (NR1), and calcineurin A (CN-A)
(Millipore). The secondary antibodies were anti-rabbit
IgG antibody conjugated with horseradish peroxidase
(HRP; GE Healthcare) and anti-mouse IgG antibody
conjugated with HRP (Jackson ImmunoResearch). En-
hanced chemiluminescence detection reagents (GE Health-
care) were used for detection. Bands were quantified using
Fujifilm LAS-3000 Luminescent Image Analyzer (Tokyo,
Japan).
Statistical analysis
The results are expressed as the mean ± standard devi-
ation (S.D.) and were analyzed by analysis of variance
(ANOVA) with post-hoc Bonferroni multiple compari-
sons tests.
Results
The neurodegeneration occurred in the hippocampus of
the KA-icv-injected mice
To explore the neurodegenerative process after KA-
injection, FJB staining of hippocampus was performed
(Figure 1a, b). The results show that the neurons were
quickly labeled by FJB (FJB-neurons) at day 1 post KA-injection. The major FJB-neurons include the pyramidal
neurons in CA1/3, and the interneurons in DG-hilus.
During the period of day 3 to 7 post KA-injection, the
number of the FJB-neurons was reduced time-dependently.
The decrease rate of the FJB-neurons in DG-hilus was fas-
ter than that in CA3. Alternatively, the number of FJB-
neurons in CA1 is not significantly altered (Figure 1b).
We use NeuN as another marker to verify the neurode-
generation. Our result observe a prominent loss of NeuN
in CA3 and DG beginning at day 3 post KA-injection, and
a transient but reversible loss at day 5 post KA-injection
in CA1 (Figure 1a and 1c).
Caspase 3 activation occurred in both neurons and glial
cells in the hippocampus of KA-icv-injected mice
To verify the contribution of the caspase-dependent
apoptosis on KA-mediated neurodegeneration, we per-
formed immunostaining by anti-active caspase 3 anti-
body (Figure 2). The results show that caspase 3 may be
activated in neurons and glial cells successively. During
the period of day 1 to 3 post KA-injection, caspase 3
was activated in the cell body of pyramidal neurons in
both CA1 and CA3. In the CA3, the colocalization of ac-
tive caspase 3 with the neurites of pyramidal neurons
was observed in the stratum radiatum. In DG, active
caspase 3 was found in the hilar interneurons at day 3
post KA-injection (Figure 2a, 2b). During the period of
day 5 to 7 post KA-injection, active caspase 3 was ob-
served in astrocytes and the radial glial cells in subgra-
nular zoon (SGZ) of DG (Figure 2a, 2c).
Astrogliosis and microglial activation is promoted in the
hippocampus of KA-icv-injected mice
To assess hippocampal astrogliosis and microglial activa-
tion, we performed immunostaining using anti-GFAP
and anti-Iba-1 antibodies (Figure 3a). Astrocytes in the
hippocampus of control mice displayed small somata
with thin processes morphologies. After KA-injection,
the cell bodies of astrocytes were enlarged, and their cell
processes were thickened. GFAP immunoreactivity (IR)
was significantly increased at day 3 post KA-injection and
with the highest expression at day 7 post KA-injection
(Figure 3b). The relative IR per field of view of GFAP in-
creased by 7.1-, 13.4- and 14.5-fold of the vehicle-injected
Figure 4 (See legend on next page.)
Tzeng et al. Journal of Biomedical Science 2013, 20:90 Page 8 of 16
http://www.jbiomedsci.com/content/20/1/90
(See figure on previous page.)
Figure 4 Caspase 3 inhibitor does not prevent the neurodegeneration in the hippocampus of the KA-icv-injected mice. CD-1 mice
received KA-icv-injections alone or co-injection of KA and caspase 3 inhibitor (Cas3I) or vehicle (veh), and were sacrificed at day 3 and 7 post
KA-injection (KA-d3 and KA-d7). For control, the mice were sacrificed at day 7 post vehicle-injection (veh). The neurodegeneration in the ipsilateral
side was examined by immunostaining with anti-active caspase 3 (aCas 3, red) and anti-NeuN (NeuN, green) antibodies. Cell nuclei were stained
with Hoechst 33258 (blue). The representative fluorescent images of the ipsilateral side of CA1, CA3 and DG are shown. The location of pyramidal
layer (Py), striatum radiatum (SR). Molecular layer (Mo), and Hilus (Hi) are indicated in the left lane of the panels.
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GFAP-stain radial glial cells in SGZ is also increased after
KA-injection.
Microglia in the hippocampus of control mice dis-
played ramified morphologies. After KA injection, the
cell bodies of a microglia were enlarged, and their cell
processes were thickened. However, the pattern of cell
number increase of microglia was different as comparing
with astrocytes (Figure 3a). The increase of Iba-1 IR was
biphasic after KA-injection (Figure 3c). The first phase
occurred at day 1 post KA-injection, and the second
phase peaked at day 5 post KA injection. Between these
two peaked phases, Iba-1 IR fall in a trough at day 3 post
KA-injection. In the second phase, the IR increased by
19.7-, 8.6- and 4.0-fold of that at day 3 post KA-
injection in CA1, CA3, and DG, respectively.
Caspase 3 activation involves in neurite structure
alteration but not in neurodegeneration
The caspase 3 inhibitor (insolution Casapase-3 Inhibitor
I, Merck) was then employed to elucidate the role of
caspase 3 activation on KA-mediated neurodegeneration.
The inhibiting target of caspase 3 inhibitor is the activity
of the active caspase 3, but not the activation of caspase
3. Therefore, after co-injection of KA and caspase 3 in-
hibitor, the biphasic activation of caspase 3 was not al-
tered by caspase 3 inhibitor (Figure 4). NeuN was
completely loss at day 3 post KA-injection, which did
not occur as KA injection alone. The structural integrity
of axon and dendrite was further examined by immuno-
staining using anti-MAP-2 and anti-tau antibody, re-
spectively [36]. The results indicate that the structural
integrity of axon and dendrite is mildly affected after
KA-injection. The co-injection of KA and caspase 3 in-
hibitor, however, seriously disturb the structural integrity
of axon and dendrite at day 3 post KA-caspase 3-
injection in CA1, CA3 and DG (Figure 5). The disturb-
ance is recovered at day 7 post KA-caspase 3-injection.
Caspase 3 activation is involved in the GFAP cleavage in
the hippocampus of KA-icv-injected mice
GFAP is the building block of astroglial intermediate fil-
aments. Levels of GFAP and its cleavage have been re-
lated to reactive gliosis and astroglial apoptosis, and may
be also related to differentiation of the radial glial cells.Therefore, we assessed hippocampal GFAP levels by im-
munoblotting (Figure 6). After KA-treatment, the level
of GFAP was significantly increased at day 3, 5, and 7
post KA-injection. Full length GFAP (52 kDa) was pro-
gressively cleaved into smaller fragments time-dependently
(Figure 6a). GFAP fragments of 45 kDa at day 1 post KA-
injection and 40 kDa at day 3 post KA-injection were
detected. The level of 45 kDa fragment increased from
4.61 ± 1.68% in the control to 82.06 ± 12.84%, 116.69 ±
30.81%, 124.58 ± 27.29% and 149.97 ± 36.75% of the con-
trol at day 1, 3, 5, and 7 post KA-injection, respectively.
The level of 40 kDa fragment increased to 3.59 ± 1.68%,
31.63 ± 25.20%, 52.58 ± 21.65% and 87.28 ± 38.79% of
52 kDa GFAP in the control at day 1, 3, 5, and 7 post
KA-injection, respectively. The co-injection of KA and
caspase 3 inhibitor inhibit 40 kDa fragment production
at day 7 post KA-caspase 3-injection (Figure 6b).
Neuroplasticity is modulated in the hippocampus of
KA-icv-injected mice
Immunoblot analysis of PSD-proteins from the brain ho-
mogenates after KA-injection showed a time-dependent
decrease of the level of PSD-95, NMDA receptor (NR)1,
glutamate receptor (GluR)1, GluR2 and SAP-102 from
day 1 to 5 post KA-injection, which are partially recov-
ered at day 7 post KA-injection (Figure 7a). To compare
the synaptic removal extent of different PSD proteins,
the decrease of NR1, GluR1, GluR2 and SAP-102 are
compared to that of PSD-95. The result shows that the
ratio of NR1/PSD-95 and SAP-102/PSD-95 is signifi-
cantly decreased during the period of day 1 to 7 post
KA-injection. The ratio of GluR1/PSD-95 and GluR2/
PSD-95 is significantly decreased and increased at day 1
and day 5 post KA-injection, respectively (Figure 7a).
Synaptic removal of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) has been
reported to be mediated by calcineurin A (CN-A) which
is proteolytically activated by caspase 3. Therefore, the
KA injection-mediated proteolysis of CN-A were exam-
ined (Figure 7b). The result shows that the active form
CN-A (36 kDa fragment) increased to 415.09 ± 59.33
and 387.37 ± 15.84% of the vehicle injection at day 5 and
7 post KA-injection, respectively. To verify the involve-
ment of caspase 3 on KA-induced proteolysis of CN-A,
caspase 3 inhibitor were co-injected with KA and the
Figure 5 (See legend on next page.)
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Figure 5 Caspase 3 inhibitor, but not KA, induces a reversible neuritic alteration in the hippocampus of the KA-icv-injected mice. CD-1
mice received KA-icv-injections alone or co-injection of KA and caspase 3 inhibitor (Cas3I) or vehicle (veh), and were sacrificed at day 3 and 7 post
KA-injection (KA-d3 and KA-d7). For control, the mice were sacrificed at day 7 post vehicle-injection (veh). The neurites in the ipsilateral side of
CA1 was examined by immunostaining with anti-MAP-2 (green) and anti tau-protein (Tau, red) antibodies. Cell nuclei were stained with Hoechst
33258 (blue). The representative fluorescent images of the ipsilateral side of CA1 are shown. The location of pyramidal layer (Py), striatum radiatum
(SR). Molecular layer (Mo), and Hilus (Hi) are indicated in the left lane of the panels.
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fragment) at day 7 post KA-injection is significantly de-
creased (Figure 7c).
Neurogenesis is significantly promoted in the
hippocampus of KA-icv-injected mice
We hypothesized that the temporal- and spatial-dependent
decline of FJB-positive signal in DG may be attributable to
neurogenesis in SGZ. Therefore, we assessed newly born
granular neurons and radial glial cells in the SGZ by im-
munostaining using anti-doublecortin (DCX) and anti-
GFAP antibody, respectively. The result shows that the
number of DCX-positive newly born neurons and radial
glial cells in SGZ are increased after KA injectionFigure 6 The cleavage of GFAP in the hippocampus of KA-icv-injected m
and were sacrificed at day 1, 3, 5, and 7 post KA-injection. For control, the mic
removed and homogenized, and the lysates were analyzed by immunoblottin
GFAP (52 kD) and its proteolytic fragments (45 and 40 kD). β-actin was use
GFAP protein (black columns), 45 kDa-fragment (gray columns) and 40 kD
vehicle treated mice (veh). The results are the mean ± S.D. from five indep
and the KA injection are indicated by *, P < 0.05; **, P < 0.01; ***, P < 0.001
and caspase 3 inhibitor (Cas3I) or vehicle (veh), and were sacrificed at day
immunoblotting. The top panel shows a representative immunoblot of GF
bottom panel shows the level of the 40 kD fragment at day 3 and 7 post
The results are the mean ± S.D. from three independent experiments. Sign
caspase 3 inhibitor are indicated by ***, P < 0.001.(Figure 8a and 8b). Both newly born neurons and radial
glial cells are increased in the period of day 1 to 7 post
KA-injection (Figure 8b).
Caspase inhibition prevents the promotion of
neurogenesis and microglial activation, but not
astrogliosis, in the hippocampus of KA-icv-injected mice
The above results indicate that KA injection promotes
caspase 3 activation and enhances neurogenesis, micro-
glial activation, proliferation of radial glial cells and astro-
gliosis in the hippocampus of mice. We thus examine the
role of caspase 3 activation at day 7 post KA-injection due
to that time point presented all four events of neurogen-
esis, microglial activation, proliferation of radial glial cellsice is caspase 3 dependent. (a) CD-1 mice received KA-icv-injections
e were sacrificed at day 7 post vehicle-injection (veh). Hippocampus was
g. The top part shows a representative immunoblot of the full length
d as internal standard. The bottom panel shows the level of total
a-fragment (white columns) relative to the level of 52-kD GFAP in
endent experiments. Significant differences between the control (veh)
. (b) ICR mice received KA-icv-injections alone or co-injection of KA
3 and 7 post KA-injection. Hippocampal lysates were analyzed by
AP and its fragments. β-actin was used as internal standard. The
KA-injection relative to the level of 40-kD GFAP in the control (veh).
ificant differences between the mice treated with and without
Figure 7 The alteration of the neuroplasticity-related proteins in the hippocampus of KA-icv-injected mice is caspase 3 dependent.
CD-1 mice received KA-icv-injections and were sacrificed at day 1, 3, 5, and 7 post KA-injection. For control, the mice were sacrificed at day 7 post
vehicle-injection (veh). Hippocampus The homogenate and PSD domain of hippocampus were prepared. The GluR2, GluR1, NR-1 and SAP-102 of
PSD domain (a) and CN-A of total hippocampal homogenate (b) were analyzed by immunoblotting. (c) CD-1 mice received KA-icv-injections
alone or co-injection of KA and caspase 3 inhibitor (Cas3I) or vehicle (veh), and were sacrificed at day 3 or 7 post KA-injection (KA-d3 and KA-d7).
Hippocampal lysates were analyzed by immunoblotting. PSD-95 and β-actin were used as internal standard for (a) and (b, c), respectively. The
top part is the representative immunoblots. The bottom part in (a) is the ratio of proteins/PSD-95 relative to the ratio of the control (veh). The
bottom part in (b) and (c) show the percentage of the level of 65 kD (open circles) and 36 kD (closed circles) relative to the level of 65 kD in the
control (veh). Results are mean ± S.D. from five independent experiments. Significant differences between the control (veh) and KA injection in
(a, b) are indicated by *, P < 0.001. Significant differences between the mice injected with and without caspase 3 inhibitor in (c) are
indicated by *, P < 0.001.
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http://www.jbiomedsci.com/content/20/1/90and astrogliosis. The suprapyramidal blade of granular layer
of DG was triple-immunostained using anti-DCX, anti-Iba-
1 and anti-GFAP antibodies to determine the newly born
neurons, microglia, astrocytes and radial glial cells, respect-
ively (Figure 8c and 8d). The result showed that the KA-
injection-mediated cell number increase of radial glial cells,
newly born neurons, and microglia are diminished by cas-
pase 3 inhibitor. The KA-injection-mediated astrogliosis is
however not affected by caspase 3 inhibitor.
Discussion
Our results demonstrate several novel-finding on cas-
pase 3-involved neurodegeneration, synaptic plasticity,
reactive gliosis, and neurogenesis in KA-mediated excito-
toxicity. KA induced an acute neurodegeneration in hippo-
campus detected by FJB-staining which occurred in CA1/
3-pyramidal neurons and DG-hilar neurons (Figure 1a, b).
The similar FJB-labeled neurodegeneration was also ob-
served in the previous study [37]. Another type of de-
layed and irreversible neurodegeneration in CA3 and
DG-hilus was also detected by the loss of NeuN expres-
sion (Figure 1a, c). KA induces different neurodegenera-
tion among CA1, CA3 and DG-hilus regions which may
be due to that the stratum lucidum region of CA3 is
highly enriched with high-affinity KA binding sites [38].
CA3 neurons are directly excited by stimulation of theirKA receptors and indirectly, by increased glutamate
efflux secondary to KA stimulation of mossy fibers
[39,40]. Therefore, the transient neurodegeneration de-
tected by the loss of NeuN expression in CA1 may be
also derived from the mild insult in CA1. It is puzzling
that the neurodegeneration (NeuN-loss) occurs transi-
ently in CA1 area at day 5 post KA injection. It can also
be explained by KA-induced a transient loss of NeuN
mRNA or protein.
It is unclear whether microglial activation initiates the
disease progression or that merely response to neuronal
death [39]. In our present study, microglia are activated
in two phase after KA-injection (Figure 3). The first
phase activation may be derived from KA-mediated exci-
totoxicity that may subsequently affect neurogenesis
[41-43], synaptic stripping [44,45], and gliosis [46,47].
Moreover, reactive glial cells produced pro- and anti-
inflammatory cytokines, chemokines, neurotrophic fac-
tors and other modulators to be involved in neuron-glia
communication. Previous studies have indicated that the
initial limbic seizures increase hippocampal neurogenesis
[14-17]. In our study, KA-mediated an acute neurogen-
esis include the proliferation of radial glial cells and in-
crease of newly born neurons (Figure 7a, b).
KA-induced non-apoptotic caspsae 3 activation is both
cell type and region specific (Figure 2) which is similar
Figure 8 Caspase 3 inhibitor prevents the KA-promoted hippocampal neurogenesis and microglial activation, but not astrogliosis, in
the KA-icv-injected mice. CD-1 mice received KA-icv-injections and were sacrificed at day 1 to 7 post KA-injection. For control, the mice were
sacrificed at day 7 post vehicle-injection (veh). (a and b) The neurogenesis and astrogliosis in the ipsilateral side of DG was examined by
anti-DCX (red) and anti-GFAP (green) antibodies. Cell nuclei were stained with Hoechst 33258 (blue). Panel (a) shows the representative GFAP
and DCX fluorescent images of DG at day 7 post KA-injection as compared with vehicle injection. Panel (b) shows the calculated number of
DCX-positive neurons in 250 μm × 250 μm field. The data are represented as the percentage related to the control (veh). (c and d) CD-1 mice
received KA-icv-injections alone (KA-7d) or co-injection of KA with caspase 3 inhibitor (KA + Cas3I-7d) or vehicle (veh), and were sacrificed at
day 7 post KA-injection. The neurogenesis, microglial activation and astrogliosis in the suprapyramidal blade of DG was examined by anti-DCX (red),
anti-GFAP (green) and anti-Iba-1 (blue) antibodies, respectively. Panel (c) shows the representative fluorescent images of GFAP, DCX and Iba-1 of DG at
day 7 post KA-injection as compared with vehicle injection. The dotted lines define the molecular layer (ML), granular layer (GL) and subgranular zone
(SGZ) of DG. Panel (d) shows the calculated number of DCX-positive neurons in the 250 μm × 250 μm field. The results are the mean ± S.D. from 8
images. Significant differences between the control (veh) and the KA injection are indicated by ***, P < 0.001. Significant differences between the KA
injection alone and the co-injection of KA and caspase 3 inhibitor are indicated by ###, P < 0.001.
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http://www.jbiomedsci.com/content/20/1/90to the previous report [48]. KA-induced caspsae 3 acti-
vation in CA1 is located in the cell body of pyramidal
neurons. In CA3, however, it is located in both cell body
of pyramidal neurons and the neurites in stratum radia-
tum. Alternatively, caspase 3 activation is located in in-
terneurons in DG-hilus. The different onset of caspase 3
activation in CA1, CA3 and DG-hilus may due to that
CA3 is highly accessible to KA-mediated excitotoxicity
[38]. A similar nuclear activation of caspase 3 in neurons
has been described previously [49,50]. Those studies
suggested that SE-mediated nuclear caspase 3 activationmay activate caspase-activated DNase (CAD) results in
DNA fragmentation and apoptosis [51]. However, cas-
pase 3 activity may be suppressed by inhibitors of apop-
totic proteins (IAP), which promotes neuronal survival
[52,53]. Previous study indicated that apoptotic caspase
3 activation following SE [32,33,48]. However, they
found that caspase 3 contributes to the cell death in only
a small proportion of degenerating cells. Henshall et. al.
[32] claimed that caspase 3 may play a significant role in
the mechanism by which neurons die following seizures.
They also found that caspase-3 inhibitor significantly
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http://www.jbiomedsci.com/content/20/1/90improved neuronal survival following seizures. However,
in their IHC data, the TUNEL-neurons were colocalized
with the IR of caspase 3, but not the activated caspase 3.
Therefore, the increased caspase3-IR may not reflect the
activated caspase 3 in the apoptotic neurons.
The non-apoptotic caspase 3 activation may also involve
in astrocyte differentiation [54,55]. Cleaved GFAP has
been previously detected during neurotoxic process, and
GFAP fragments have also been identified as the head do-
main cleaved GFAP by calpain or caspase 3 [27,29]. We
assessed hippocampal GFAP levels by immunoblotting
(Figure 6a). GFAP-IR was significantly increased after KA-
injection. Full length GFAP (52 kDa) was progressively
cleaved into smaller fragments of 45 kDa and 40 kDa by
calpain and caspase 3, respectively. The KA-mediated
production of 40 kDa fragment was inhibited by the co-
injection of caspase 3 inhibitor (Figure 6b) confirm the
involvement of caspase 3.
The express of active caspase 3 in the GFAP-positive ra-
dial glial cells increased after KA-injection suggests that
caspase 3 functions as a regulatory molecule in neurogen-
esis [56,57]. The co-injection of caspase 3 inhibitor pre-
vent KA-mediated increase of radial glial cells, newly born
neurons, and activated microglia, but not the astrogliosis,
suggesting that astroglial caspase 3 was activated after
gross astrogliosis, which then regulate microglial activa-
tion and neurogenesis. Microglia has been described to be
a mediator of neurogenesis [42]. Thus the first phase
microglial activation may involve the KA-mediated neuro-
genesis, and which was inhibited by caspase 3 inhibitor.
Further investigation is needed to determine key compo-
nents of this potential mechanism of astrogliosis, includ-
ing the subcellular localization of active caspases, the
identity of relevant transcription factors, and the relation-
ships between these components and regulation of specific
factors such as glutamine synthetase and fibroblast growth
factor-2 [57]. In the reactive neonatal astrocyte cultures,
specific inhibition of caspases 3 attenuated glutamine syn-
thetase and fibroblast growth factor-2 expression, but did
not reverse the morphological reactive phenotype may ex-
plain why caspase 3 inhibitor did not alter astrogliosis in
our study.
Caspase 3 has been implicated in synaptic remodeling
[24,28,58], cell differentiation [26,59], and cytoskeletal
remodeling [25,60,61]. We detected the non-apoptotic
caspase 3 activities in post synaptic density, which trig-
gered the dominant removal of the GluR1 and SAP-120,
but not GluR2 and NR1 from postsynaptic sites. These
molecular modifications may correlate with spine degen-
eration [62]. Proteolytic cleavage of CN-A was signifi-
cantly reduced when caspase 3 was inhibited, confirming
the direct involvement of caspase 3 activation in the
dendritic plasticity alteration and astrogliosis after KA-
injection. These molecular modifications may correlatewith spine degeneration which was observed via the
GluR1 removal from PSD and the proteolytic activation of
CN-A in hippocampus [63]. Our study is the first time to
reveal a caspase 3-dependent mechanism that contributes
to synaptic molecular change in KA-mediated neurotox-
icity. A similar synaptic modification was described in a
mouse model of Alzheimer’s disease [64].
The KA-mediated neuroplasticity alteration was de-
tected by examining the loss of the PSD-proteins, espe-
cially the GluR1, in the PSD domain. Therefore, the
activation of caspase 3 may be important for the integrity
of neurites which is required for the neuroplasticity. How-
ever, the neuritic structures were disturbed seriously by
the injection of KA combined with caspase 3 inhibitor but
not by KA alone (Figure 5). Therefore, neuroplasticity al-
teration was detected by the proteolytic activation of CN-
A. The result indicated that the proteolytic activation of
CN-A was inhibited by the co-injected caspase 3 inhibitor
(Figure 6b, c).
Conclusions
Our results provide the first direct evidence of a causal
role of caspase 3 activation in the cellular changes during
KA-mediated excitotoxicity. These findings may highlight
novel pharmacological strategies to arrest disease progres-
sion and control seizures that are refractory to classical
anticonvulsant treatment.
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